Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

SRR8942976

—

388a040e-b4b7-55ac-8edf-1257e36617d9

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
  • INFLAMMATORY_RESPONSE+0.380
  • TNFA_SIGNALING_VIA_NFKB+0.360
  • ANGIOGENESIS+0.340
  • KRAS_SIGNALING_UP+0.340
  • UV_RESPONSE_DN+0.330
  • HEDGEHOG_SIGNALING+0.320
  • IL6_JAK_STAT3_SIGNALING+0.320
  • ALLOGRAFT_REJECTION+0.290
  • IL2_STAT5_SIGNALING+0.290

Top 10 suppressed

  • E2F_TARGETS-0.550
  • G2M_CHECKPOINT-0.510
  • MYC_TARGETS_V1-0.400
  • OXIDATIVE_PHOSPHORYLATION-0.380
  • GLYCOLYSIS-0.360
  • MTORC1_SIGNALING-0.360
  • MITOTIC_SPINDLE-0.350
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.280
  • DNA_REPAIR-0.270
  • SPERMATOGENESIS-0.270

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-98-A53C-01A-11R-A262-07
lung-landscapes@6
—cohortMD20.919
2TCGA-98-A53D-01A-32R-A262-07
lung-landscapes@6
—cohortMD20.917
3TCGA-55-7574-01A-11R-2039-07
lung-landscapes@6
—cohortMD20.917
420020074.LumA
breast-umap@18
—A0.917
5TCGA-E2-A1IJ-01A-11R-A144-07
breast-umap@18
—A0.915
6TCGA-LL-A440-01A-11R-A24H-07
breast-umap@18
—A0.909
7TCGA-4Z-AA7N-01A-11R-A39I-07
bladder-landscape@3
——0.908
8TCGA-S2-AA1A-01A-12R-A39D-07
lung-landscapes@6
—cohortA10.903
9TCGA-60-2715-01A-01R-0851-07
lung-landscapes@6
—cohortSQ10.901
10TCGA-CN-4728-01A-01R-1436-07
head-neck@1
——0.900

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.450Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.380Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.360Inavolisib— uncovered
ANGIOGENESIS0.340Remibrutinib— uncovered
KRAS_SIGNALING_UP0.340Inavolisib— uncovered
UV_RESPONSE_DN0.330Inavolisib— uncovered
HEDGEHOG_SIGNALING0.320Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.320Inavolisib— uncovered
ALLOGRAFT_REJECTION0.290Idelalisib— uncovered
IL2_STAT5_SIGNALING0.290Idelalisib— uncovered
MYOGENESIS0.280Inavolisib— uncovered
COAGULATION0.220Binimetinib— uncovered
COMPLEMENT0.220Inavolisib— uncovered
APICAL_SURFACE0.190Temsirolimus— uncovered
TGF_BETA_SIGNALING0.160Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.160Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.090Idelalisib— uncovered
KRAS_SIGNALING_DN0.080Remibrutinib— uncovered
XENOBIOTIC_METABOLISM0.070Inavolisib— uncovered
APOPTOSIS0.060Idelalisib— uncovered